Table 2.

Relationship between family history of breast cancer and risk of different histologic types of breast cancer

Controls (n = 4,426)Ductal (n = 3,302)
Lobular (n = 263)
Ductal-lobular (n = 246)
Medullary (n = 84)
Tubular (n = 72)
Comedo (n = 68)
Mucinous (n = 57)
nnOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)
First-degree family history of breast cancer: all women
No3,9402,6771.0 (ref)2091.0 (ref)1951.0 (ref)711.0 (ref)581.0 (ref)561.0 (ref)501.0 (ref)
Yes4866251.9 (1.7-2.2)*541.9 (1.4-2.6)*512.1 (1.5-2.9)*131.7 (0.9-3.1)141.8 (1.0-3.3)*121.9 (1.0-3.6)*71.0 (0.5-2.3)
Phomogeneity = 0.77
Controls (n = 1,740)
Ductal (n = 1,379)
Lobular (n = 90)
Ductal-lobular (n = 113)
Medullary (n = 44)
Tubular (n = 24)
Comedo (n = 33)
Mucinous (n = 18)
nn
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
First-degree family history of breast cancer: premenopausal women
No1,7831,3081.0 (ref)751.0 (ref)921.0 (ref)351.0 (ref)191.0 (ref)291.0 (ref)171.0 (ref)
Yes1762662.1 (1.7-2.5)*151.9 (1.1-3.5)*212.3 (1.4-3.9)*113.5 (1.7-7.0)*72.9 (1.2-6.8)*62.2 (0.9-5.4)42.1 (0.7-6.5)
Phomogeneity = 0.88

Controls (n = 1,703)
Ductal (n = 1,232)
Lobular (n = 145)
Ductal-lobular (n = 115)
Medullary (n = 22)
Tubular (n = 33)
Comedo (n = 19)
Mucinous (n = 26)
nn
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
n
OR (95% CI)
First-degree family history of breast cancer: postmenopausal women
No1,6571,0541.0 (ref)1131.0 (ref)881.0 (ref)221.0 (ref)261.0 (ref)171.0 (ref)251.0 (ref)
Yes2542901.8 (1.5-2.1)*321.7 (1.1-2.6)*272.0 (1.3-3.2)*10.3 (0.1-2.2)71.6 (0.7-3.8)52.1 (0.8-5.8)30.7 (0.2-2.4)
Phomogeneity = 0.51
Pinteraction = 0.15
  • NOTE: All ORs are adjusted for age, race, and study site.

  • * P < 0.05.

  • Phomogeneity in the ORs across the six different histologic types of breast cancer.

  • Pinteraction between menopausal status and first-degree family history of breast cancer in relation to risk of different histologic types of breast cancer based on likelihood ratio testing.